by Clinical Neuropsychologist Online | Tuesday, March 26, 2024 | Dementia
Alzheimer’s &Dementia, EarlyView. If you do not see content above, kindly GO TO SOURCE. Not all publishers encode content in a way that enables republishing at Neuro.vip. This post is Copyright: Susanne J. van Veluw, Michael J. Young | March 26, 2024 Wiley:...
by Clinical Neuropsychologist Online | Tuesday, March 26, 2024 | Dementia
Abstract INTRODUCTION Glial fibrillary acidic protein (GFAP) in plasma is a proxy for astrocytic activity and is elevated in amyloid-β (Aβ)-positive individuals, making GFAP a potential blood-based biomarker for Alzheimer’s disease (AD). METHODS We assessed...
by Clinical Neuropsychologist Online | Saturday, March 23, 2024 | Dementia
Abstract INTRODUCTION Tau aggregation into paired helical filaments and neurofibrillary tangles is characteristic of Alzheimer’s disease (AD) and related disorders. However, biochemical assays for the quantification of soluble, earlier-stage tau aggregates are...
by Clinical Neuropsychologist Online | Thursday, March 21, 2024 | Dementia
Abstract INTRODUCTION Genome-wide association studies (GWAS) have identified loci associated with Alzheimer’s disease (AD) but did not identify specific causal genes or variants within those loci. Analysis of whole genome sequence (WGS) data, which interrogates...
by Clinical Neuropsychologist Online | Wednesday, March 20, 2024 | Dementia
Abstract BACKGROUND Variants in ABCA7, a member of the ABC transporter superfamily, have been associated with increased risk for developing late onset Alzheimer’s disease (LOAD). METHODS CRISPR-Cas9 was used to generate an Abca7V1613M variant in mice, modeling...
